Are ACE inhibitors and ARBs more beneficial than harmful in the treatment of severe COVID-19 disease?
<p>After starting in China four months ago, the COVID-19 pandemic now affects most countries and has already caused more than 200,000 deaths by April 26, 2020</p><p>Under chest computerized tomography scans, the majority of severe COVID-19 patients show bilateral ground glass-like...
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Journal of Cardiovascular Medicine and Cardiology - Peertechz Publications,
2020-05-05.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| Gaia: | <p>After starting in China four months ago, the COVID-19 pandemic now affects most countries and has already caused more than 200,000 deaths by April 26, 2020</p><p>Under chest computerized tomography scans, the majority of severe COVID-19 patients show bilateral ground glass-like opacities and subsegmental areas of consolidation indicative of pneumonia. If in its severe forms this disease affects the lungs, in many cases it is also responsible for a multi-organ failure with adverse myocardial remodeling, myocardial stress, and cardiomyopathy [1,2]. </p> |
|---|---|
| DOI: | 10.17352/2455-2976.000122 |